Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-14

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression.

The researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool.

The study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance.

Participants will:

* Use the reminiscence app for 25 days for 10-15 minutes.
* Have a primary caregiver help personalize the app by sharing family memories, other relatives may optionally contribute in a private group.
* Complete brief questionnaires at the start and during follow-up routine visits (for example, apathy and depression scales, sleep, and quality of life).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Visuospatial Attention, Eye Movements and Instrumental Activities of Daily Living (IADLs) in Alzheimer's Disease

NCT02941289

Alzheimer's Disease

UNKNOWN NA

Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia

NCT06149013

Mild Cognitive Impairment Mild Dementia

COMPLETED NA

Multidomain Interventions Via Face-to-face and Video Communication Platforms in Mild Cognitive Impairment

NCT05023057

Mild Cognitive Impairment

COMPLETED NA

A Cognitive Training Tool Based on Life-logging in Mild Cognitive Impairment (ReMemory-MCI)

NCT02592187

Mild Cognitive Impairment

UNKNOWN NA

Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease

NCT02176629

MCI Alzheimer's Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurocognitive Disorders, Mild Cognitive Impairment, Mild Depression Mild Apathy Apathy in Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DRT Users

Single observational cohort exposed to a personalized digital reminiscence therapy, through daily 10-15 minute sessions.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women over 60 years of age.
* DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes.
* Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 26.
* Presence of mild depression, or presence of mild apathy, or presence of both
* Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool.
* Having voluntarily and informedly agreed to participate in the study (signed written consent).
* Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool).
* Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access.
* Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group.
* Subjects covered by a social security scheme.

Exclusion Criteria

* Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD.
* Presence of major psychiatric disorders (e.g., schizophrenia, moderate to severe major depressive episode, bipolar disorder).
* Major hearing or visual impairments.
* History of premorbid intellectual disability.
* Patients under guardianship, conservatorship, or legal protection.
* Patients who have already used the Lilia app
* Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study.
* Patients who have received a new treatment related to neurocognitive disorders (medication or other) during the 3 months prior to the inclusion visit.

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No